Treatment & Doctors

Peritoneal Mesothelioma Specialist Takes Expertise to South Florida

Written By:
May 10, 2018
Fact Checked
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.
Written By: Tim Povtak,
May 10, 2018

Dr. Shanel Bhagwandin saw the steady flow of patients who traveled from Southeast Florida to New York’s renowned Mount Sinai Hospital for the specialized treatment of peritoneal mesothelioma cancer.

He knew there was a better way, and he just made it happen.

Bhagwandin made the 1,200-mile move himself — from Mount Sinai to the Jupiter Medical Center — to start the latest surgical oncology program that specializes in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).

“This procedure can make a tremendous difference,” Bhagwandin told “And it makes a world of difference for a patient and his family when they don’t have to go across the country to get the treatment they need.”

Procedure Key for Mesothelioma Treatment

Bhagwandin, who grew up in South Florida, has spent considerable time at the Jupiter Medical Center raising awareness of his program with patients and medical professionals.

The cytoreduction and HIPEC combination has become a key strategy in treating a variety of abdominal malignancies. Its effectiveness has allowed peritoneal mesothelioma patients to survive considerably longer than ever before.

Many today are living five to 10 years and beyond, which was unheard of a decade ago.

According to one study involving more than 100 patients at the Columbia University Medical Center, the median overall survival rate was 6.65 years. And 30 percent of the patients had a survival estimate of more than 10 years.

An earlier, larger study produced an overall median survival of 53 months for those who underwent the cytoreduction and HIPEC combination.

By comparison, patients who receive only systemic chemotherapy — which is the majority of patients with peritoneal mesothelioma — typically survive less than two years.

Procedure Requires a Specialist

Many patients, and even oncologists, approach mesothelioma with a hopeless view.

And in the majority of cancer centers around the country, the cytoreduction and HIPEC combination is not even available.

“It’s important for us to make ourselves available, to let people know what is out there for them,” he said. “For a patient, being close is of paramount importance. For everything these patients have to go through, they need the support of families close by.”

Although the physical distance between the two facilities is vast, the Jupiter Medical Center is part of the Mount Sinai Health Network, allowing for a variety of shared resources, including clinical trials.

Even in Jupiter, Bhagwandin remains the medical director of surgical oncology network development at Mount Sinai. He also is an assistant professor in the Department of Surgery at the Icahn School of Medicine at Mount Sinai.

He participates regularly in a national HIPEC tumor board meeting, which allows oncologists around the country to freely discuss cases and treatment ideas.

‘Something They’ve Never Heard Before’

Cytoreductive surgery, which is still evolving, is a complex procedure that can last up to 10 hours. It includes meticulously removing all visible tumor cells throughout the abdominal cavity. It may involve removing parts of various organs, including the liver, intestines, stomach and spleen.

HIPEC immediately follows the cytoreduction. It involves a heated chemotherapy solution that is pumped directly into the abdominal cavity, where it is circulated for up to 90 minutes before it is drained.

The idea of HIPEC is that by delivering high-dose chemotherapy directly to the abdomen cavity, it will kill any microscopic tumor cells left behind after surgery, something that systemic chemotherapy can’t do.

“You may not be able to use the word cure, but when you tell a patient [with this procedure] there is a chance you’ll come out of the operating room with no disease left inside, it’s something they’ve never heard before,” Bhagwandin said. “That’s powerful.”

Bhagwandin has five cytoreductive surgery and HIPEC combination procedures scheduled for May, a clear sign that his move to Jupiter was needed.

“Patients, obviously, will go anywhere and everywhere to find the right treatment option,” he said. “To be able to offer this now close by, by someone who has the expertise in it, is important.”

Medically Reviewed by Top Mesothelioma Doctors
Free Mesothelioma Guide